BRPI0705630B8 - configuração lipossomal funcional e processo de obtenção de configuração lipossomal funcional - Google Patents

configuração lipossomal funcional e processo de obtenção de configuração lipossomal funcional

Info

Publication number
BRPI0705630B8
BRPI0705630B8 BRPI0705630A BRPI0705630A BRPI0705630B8 BR PI0705630 B8 BRPI0705630 B8 BR PI0705630B8 BR PI0705630 A BRPI0705630 A BR PI0705630A BR PI0705630 A BRPI0705630 A BR PI0705630A BR PI0705630 B8 BRPI0705630 B8 BR PI0705630B8
Authority
BR
Brazil
Prior art keywords
functional liposomal
liposomal configuration
functional
polynucleotides
configuration
Prior art date
Application number
BRPI0705630A
Other languages
English (en)
Inventor
A M Coelho Castelo Arlete
Lopes Silva Célio
Gaziola De La Torre Lucimara
Helena Andrade Santana Maria
Silva Rosada Rogério
Original Assignee
Univ Estadual Campinas Unicamp
Univ Sao Paulo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Estadual Campinas Unicamp, Univ Sao Paulo filed Critical Univ Estadual Campinas Unicamp
Priority to BRC10705630A priority Critical patent/BRPI0705630F8/pt
Priority to PCT/BR2008/000387 priority patent/WO2009073941A2/en
Publication of BRPI0705630A2 publication Critical patent/BRPI0705630A2/pt
Publication of BRPI0705630E2 publication Critical patent/BRPI0705630E2/pt
Publication of BRPI0705630B1 publication Critical patent/BRPI0705630B1/pt
Publication of BRPI0705630F1 publication Critical patent/BRPI0705630F1/pt
Publication of BRPI0705630B8 publication Critical patent/BRPI0705630B8/pt
Publication of BRPI0705630F8 publication Critical patent/BRPI0705630F8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

configuração lipossomal funcional e processo de obtenção de configuração lipossomal funcional a invenção apresenta um produto para terapia e vacinação, constituído de uma configuração lipossomal funcional contendo polinucleotídeos complexados preferencialmente na superfície externa de lipossomas do tipo drvs, e o seu processo de produção. essa configuração lipossomal funcional contendo polinucleotídeos possui propriedades de mucoadesão que permite a administração através de vias não invasivas como a via nasal, e é capaz de carrear eficientemente os polinucleotídeos até o interior das células, liberando- os no citoplasma. essas propriedades potencializam maior eficiência de ação in vivo dos polinucleotídeos carreados, redução da concentração e freqüência de doses, e, no caso da vacinação produz proteção contra a doença específica
BRC10705630A 2007-12-12 2007-12-12 Processo de produção de vacina gênica lipossomal, vacina gênica lipossomal e uso da mesma BRPI0705630F8 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BRC10705630A BRPI0705630F8 (pt) 2007-12-12 2007-12-12 Processo de produção de vacina gênica lipossomal, vacina gênica lipossomal e uso da mesma
PCT/BR2008/000387 WO2009073941A2 (en) 2007-12-12 2008-12-12 Ternary liposomal composition containing a polynucleotide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRC10705630A BRPI0705630F8 (pt) 2007-12-12 2007-12-12 Processo de produção de vacina gênica lipossomal, vacina gênica lipossomal e uso da mesma

Publications (6)

Publication Number Publication Date
BRPI0705630A2 BRPI0705630A2 (pt) 2010-12-28
BRPI0705630E2 BRPI0705630E2 (pt) 2011-03-09
BRPI0705630B1 BRPI0705630B1 (pt) 2020-09-24
BRPI0705630F1 BRPI0705630F1 (pt) 2021-03-30
BRPI0705630B8 true BRPI0705630B8 (pt) 2021-05-25
BRPI0705630F8 BRPI0705630F8 (pt) 2022-01-18

Family

ID=40755920

Family Applications (1)

Application Number Title Priority Date Filing Date
BRC10705630A BRPI0705630F8 (pt) 2007-12-12 2007-12-12 Processo de produção de vacina gênica lipossomal, vacina gênica lipossomal e uso da mesma

Country Status (2)

Country Link
BR (1) BRPI0705630F8 (pt)
WO (1) WO2009073941A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2661253T3 (pl) * 2011-01-04 2017-08-31 Archivel Farma, Sl Preparat liposomowy odpowiedni do leczenia lub zapobiegania gruźlicy
TW202228727A (zh) * 2020-10-01 2022-08-01 德商拜恩迪克公司 適用於治療之微脂體ｒｎａ調配物之製備及儲存

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384923B2 (en) * 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes
US6110745A (en) * 1997-07-24 2000-08-29 Inex Pharmaceuticals Corp. Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
EP1845944A4 (en) * 2005-02-08 2011-07-27 Id Biomedical Corp Of Quebec C O B As Glaxosmithkline Biolog North America PHARMACEUTICAL COMPOSITIONS

Also Published As

Publication number Publication date
WO2009073941A3 (en) 2009-08-27
BRPI0705630F8 (pt) 2022-01-18
BRPI0705630F1 (pt) 2021-03-30
BRPI0705630E2 (pt) 2011-03-09
WO2009073941A2 (en) 2009-06-18
BRPI0705630B1 (pt) 2020-09-24
BRPI0705630A2 (pt) 2010-12-28

Similar Documents

Publication Publication Date Title
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
BR112014016165A8 (pt) compostos de benzaldeído substituído e métodos para seu uso no aumento da oxigenação do tecido
SV2010003497A (es) Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis
MX2016005574A (es) Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.
MX2020003719A (es) Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.
DOP2016000175A (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
IL227623B (en) Nanoparticle compositions comprising a population of particles, for use in the manufacture of a topical medicament for treating a subject suffering from or susceptible to a condition or disorder associated with sweat glands and/or sebaceous glands
CO6741212A2 (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
CY1114215T1 (el) Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης
BR112015007647A2 (pt) derivados de quetamina
CR11455A (es) Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades
UY30282A1 (es) Compuestos quimicos
UY30901A (es) Nuevos metodos
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
CO2017004994A2 (es) Análogos de urea unidos sustituidos como moduladores de sirtuina
EA201892536A1 (ru) Фармацевтические носители, содержащие микрорнк, для применения в лечении фиброзных заболеваний, вызванных гипергликемией
EA201290843A1 (ru) Применение изохинолонов для получения лекарственных средств, новые изохинолоны и способ их синтеза
MX2019005104A (es) Composiciones de zinc-y-pga y métodos para tratar el cancer.
CL2012001671A1 (es) Compuestos derivados de (metilsulfonil)-etil-bencenoisoindolina; composicion farmaceutica que los comprende, uso en el tratamiento del cancer, dolor, trastornos del snc, enfermedades dermatologicas, entre otras.
PE20180928A1 (es) Sales y profarmacos de 1-metil-d-triptofano
MX2016009217A (es) Inmunoterapia basada en liposomas.
CO6390103A2 (es) Combinación antitumoral que comprende cabazitaxel y capecitabina
UY31768A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre
BRPI0705630B8 (pt) configuração lipossomal funcional e processo de obtenção de configuração lipossomal funcional
BRPI1011851A2 (pt) Composto, composição farmacêutica, e, métodos para induzir apoptose em uma célula, epara tratar uma doença

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06V Preliminary requirement: patent application procedure suspended [chapter 6.22 patent gazette]
B06J Correction of requirement [chapter 6.10 patent gazette]

Free format text: O PRESENTE PEDIDO TEVE UMA PARECER DE EXIGENCIA 6.22 NOTIFICADO NA RPI NO 2569 DE 31-03-2020, TENDO SIDO CONSTATADO QUE O MESMO NAO FOI DISPONIBILIZADO, ASSIM REPUBLICO A REFERIDA PUBLICACAO.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B09A Decision: intention to grant [chapter 9.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: REFERENTE A 13A ANUIDADE.

B24D Patent annual fee: restoration after fee payment

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/12/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.